FTC 'Close' To Final PBM Insulin Price Deal With OptumRx
Federal Trade Commission staffers have signaled that they're near a settlement with UnitedHealth Group Inc.'s OptumRx that would close out the agency's in-house case accusing pharmacy benefit managers of inflating insulin...To view the full article, register now.
Already a subscriber? Click here to view full article